Kauffman Michael 4

What Happened

• Michael Kauffman, a director of Kyntra Bio, was granted a derivative award on 2026-06-12 giving him rights to 7,000 shares. The grant is reported at a $0.00 acquisition price (i.e., an equity award/option rather than an open‑market purchase) and therefore shows $0 cash paid at grant.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-17 (appears to be filed 1 business day late under the 2-business-day rule).
• Security/transaction: Grant/award (derivative option) for 7,000 shares; reported price $0.00.
• Vesting: Shares subject to the option vest in four equal quarterly installments measured from the grant date (footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing accession: 0001364719-26-000004.

Context

• This was an equity compensation grant to a director, not a market purchase or sale. Such grants are common for board compensation and reflect compensation practices rather than an immediate buy/sell signal. The option vests over the next four quarters; there is no indication the awards were exercised or sold.